INTRODUCTION
In managing the progressive nature of type 2 diabetes mellitus (T2DM) through insulin therapy, treatment intensification is often required. When a basal insulin analog is no longer enough to maintain glycemic control, patients mainly follow one of two treatment options. One of these is the addition of separate bolus insulin injections (a basal-bolus approach); however, patients can find this difficult due to the complexity arising from the separate titration of two different insulin formulations [1] . The alternative approach of switching to premixed insulins [2] shows superior glycemic control to basal insulin but is associated with reduced fasting plasma glucose (FPG) control and, in some studies, less overall reduction in glycated hemoglobin (HbA 1c ), compared to basal-bolus insulin treatment [3] [4] [5] .
One reason for these findings may be the non-optimal pharmacokinetic and pharmacodynamic characteristics of premixed formulations, which consistently use protaminated insulins for the basal insulin component, resulting in greater variability, a prolonged glucose-lowering effect beyond the time required for prandial control, and a shorter duration of action compared to basal insulin analogs [6] [7] [8] [9] [10] . Until now, it has not been possible to co-formulate a basal and a shortacting insulin analog due to interactions between the two insulins that blunt absorption, particularly that of the shortacting insulin [11] . Insulin glargine is soluble at an acidic pH of 4, which has prevented a coformulation with bolus insulins that are soluble at a neutral pH of 7.4. Similarly, co-formulation of insulin detemir with rapid-acting insulin analogs has been shown to result in the formation of mixed hexamers displaying a pharmacokinetic/pharmacodynamic profile unsuitable for optimum glycemic control [11] .
Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of two distinct insulin analogs in the ratio 70% insulin degludec (IDeg) to 30% insulin aspart (IAsp) [12] . Figure 1 [13] [14] [15] shows the mechanism of action of IDegAsp whereby IAsp is rapidly absorbed into the circulation [16] , while IDeg provides stable coverage of basal insulin needs due to its flatter and more consistent pharmacodynamic profile with a duration of action exceeding 42 h and four times less within-subject variability compared to insulin glargine [13, 17, 18] . 
As a result of the

MATERIALS AND METHODS
Study Design
This 
Interventions
The trial consisted of a screening visit (Visit 1), followed by a treatment period (Visits 2-8), and a follow-up visit (Visit 9). After screening, all subjects received IDeg (0.42 U/kg) once daily for 5 days to reach steady state [20] . IAsp was given as required, which enabled individualization of (100 U/mL) and administered using a syringe and needle.
After administration of IDegAsp on Day 6, the steady-state pharmacodynamic response was evaluated using a 30-h euglycemic glucose clamp performed with a Biostator Ò device (MTB Medizintechnik, Amstetten, Germany), as described previously [18] . In brief, 5-6 h before dosing of the trial product, subjects received a Serum IAsp concentrations were quantified using a validated IAsp-specific enzyme-linked immunosorbent assay (ELISA). Serum IDeg concentrations were measured using a validated IDeg-specific sandwich ELISA.
Assessments
The primary endpoint was the total glucoselowering effect estimated by the area under the GIR curve during one 24- GIR effect. The parameters of the model were estimated in a population pharmacokinetic/ pharmacodynamic setting, using a nonlinear mixed-effects approach, which allowed individual sets of parameters to be obtained for each of the subjects included in the trial. Using the estimated individual parameters, a simulation of twice-daily multiple dosing was conducted to obtain a mean steady-state profile. Twice-daily multiple dosing for 6 days at a dose level of 0.3 U/kg was simulated for each of the subjects, and the mean of the profiles on Day 6 was subsequently calculated. A dose of 0.3 U/kg was used for the simulation based on the assumption that the once-daily dose of 0.6 U/kg would be divided into two for the twice-daily dose. The modeling was performed using NONMEM Ò version 7. Safety analyses were based on the safety analysis set (all subjects who received C1 dose of either IDeg or IDegAsp). Safety endpoints were summarized using descriptive statistics.
RESULTS
Subject Characteristics
Of the 25 subjects screened, a total of 22 subjects (18 men, 4 women) with T1DM were exposed to IDeg and IDegAsp during the trial. No subjects withdrew from the trial. The mean age of the subjects was 40 years (range 20-56 years), mean HbA 1c was 7.9% (range 5.8-9.0%), mean duration of diabetes was 23.1 years (range 8.9-42.9 years), and mean BMI was 24.6 kg/m 2 (range 20.2-27.9 kg/m 2 ) (Table 1) .
Pharmacodynamics
The mean GIR profile at steady state is shown in Mean blood glucose levels remained at the clamp target level throughout the euglycemic clamp procedure (Fig. 3) . No subject experienced end of action (defined as a blood glucose level 
Safety
During 5 days of IDeg administration, one adverse event was reported that was considered Fig. 2 Mean glucose infusion rate profile of once-daily insulin degludec/insulin aspart (IDegAsp) administered at steady state in subjects with type 1 diabetes. OD, once daily 
DISCUSSION
At steady state, the glucose-lowering effects of the prandial and basal components of IDegAsp were distinct and clearly separated. The IAsp component resulted in a rapid onset of action and a peak glucose-lowering effect covering the prandial phase, providing mealtime insulin control. This was followed by a stable, flat and ultra-long glucose-lowering effect due to IDeg that was maintained for [30 h in all trial subjects. These properties were consistent with those observed for the individual components [16, 23] .
Historically, it has proven difficult to combine two different insulin analogs in one co-formulation, largely owing to interactions between them that blunt absorption, especially of the short-acting insulin [11] . In contrast, our findings show that IDegAsp has a distinct peak action (IAsp) followed by a separate stable and sustained basal effect (IDeg). This is reflective of the distinct mode of action of IDegAsp (see Fig. 1 ).
In the present study, the pharmacodynamic evaluation of IDegAsp was conducted at steady state due to the ultra-long duration of action of IDeg. As a result of this duration of action, metabolic action from the previous IDeg injection was still in effect when IDegAsp was injected (the mean GIR at time-point 0 was around 2 mg/kg/min as indicated in Fig. 2 ). In addition, no early termination of the 30-h clamp was required by any study subject and the duration of action exceeded 30 h in all patients.
IDeg is indicated for once-daily dosing, whereas IDegAsp may be administered once or twice daily with the main meal(s) according to patient needs and preferences [12, 24] . The current study was not powered to assess safety and tolerability. However, among the 22 patients enrolled, IDegAsp was well tolerated, there were no injection site reactions and no unexpected safety issues were identified.
The main limitation of this study was its uncontrolled design. Additional potential limitations include that some study subjects The aim of the present study was to examine the IDegAsp profile under steady-state conditions. The GIR profiles from the single-dose study [30] and the current study at steady state (Fig. 2) displayed the same shape, although, as expected, the baseline level was higher at steady state compared to the single-dose profile.
In 
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